{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:29:57Z","timestamp":1791041397333,"version":"4.1.0"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,3,1]]},"DOI":"10.2169\/internalmedicine.5119-20","type":"journal-article","created":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T22:07:02Z","timestamp":1614550022000},"page":"731-738","source":"Crossref","is-referenced-by-count":17,"title":["Rituximab-induced Ileocolitis in a Patient with Gastric MALToma: A Case Report and Literature Review"],"prefix":"10.2169","volume":"60","author":[{"given":"Yoshikazu","family":"Tsuzuki","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Saitama Medical University, Japan"},{"name":"Department of General Internal Medicine, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Shiomi","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Ashitani","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Miyaguchi","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Osaki","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Ohgo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saitama Medical University, Japan"},{"name":"Department of General Internal Medicine, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketo","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetomo","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Imaeda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Saitama Medical University, Japan"},{"name":"Department of General Internal Medicine, Saitama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445, 1994.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"2","unstructured":"2. Salles G, Barrett M, Fo\u00e0 R, et al. Rituximab in B-Cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 34: 2232-2273, 2017."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Salar A. Gastric MALT lymphoma and Helicobacter pylori. Med Clin (Barc) 152: 65-71, 2019.","DOI":"10.1016\/j.medcle.2018.09.009"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mallepally N, Abu-Sbeih H, Ahmed O, et al. Clinical features of rituximab-associated gastrointestinal toxicities. Am J Clin Oncol 42: 539-545, 2019.","DOI":"10.1097\/COC.0000000000000553"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy--rare but there! Leuk Lymphoma 50: 1083-1095, 2009.","DOI":"10.1080\/10428190902934944"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shahmohammadi S, Sahraian MA, Shahmohammadi A, Doosti R, Zare-Mirzaie A, Naser Moghadasi A. A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review. Mult Scler Relat Disord 22: 22-26, 2018.","DOI":"10.1016\/j.msard.2018.02.030"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Morita K, Shibano T, Maekawa K, et al. Crohn&apos;s disease following rituximab treatment in a patient with refractory nephrotic syndrome. CEN Case Rep 8: 55-60, 2019.","DOI":"10.1007\/s13730-018-0364-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Eckmann JD, Chedid V, Quinn KP, Bonthu N, Nehra V, Raffals LE. De novo colitis associated with rituximab in 21 patients at a tertiary center. Clin Gastroenterol Hepatol 18: 252-253, 2020.","DOI":"10.1016\/j.cgh.2019.03.027"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Blombery P, Prince HM, Levinson M, Pianko S, Maxwell E, Bhathal P. Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma. J Clin Oncol 29: e110-e112, 2011.","DOI":"10.1200\/JCO.2010.31.8899"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Uzzan M, Ko HM, Rosenstein AK, Pourmand K, Colombel JF, Mehandru S. Efficient long-term depletion of CD20+ B cells by rituximab does not affect gut-resident plasma cells. Ann N Y Acad Sci 1415: 5-10, 2018.","DOI":"10.1111\/nyas.13577"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics 126: e243-e246, 2010.","DOI":"10.1542\/peds.2009-3395"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 60: 1520-1526, 2011.","DOI":"10.1136\/gut.2010.225482"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wei B, Velazquez P, Turovskaya O, et al. Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc Natl Acad Sci U S A 102: 2010-2015, 2005.","DOI":"10.1073\/pnas.0409449102"},{"key":"14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/gut.2007.138305","volume":"57","author":"D El Fassi","year":"2008","unstructured":"14. El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Heged\u00fcs L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves&apos; disease. Gut 57: 714-715, 2008.","journal-title":"Gut","ISSN":"https:\/\/id.crossref.org\/issn\/0017-5749","issn-type":"print"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Varma P, Falconer J, Aga A, Prince HM, Pianko S. Rituximab-induced Crohn&apos;s disease. Scand J Gastroenterol 52: 606-608, 2017.","DOI":"10.1080\/00365521.2017.1280530"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Fraser D, Boyle S, Amft N. Perianal Crohn disease after treatment with rituximab for active granulomatosis with polyangiitis. J Rheumatol 43: 2199-2200, 2016.","DOI":"10.3899\/jrheum.160456"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol 12: 597-605, 2000.","DOI":"10.1093\/intimm\/12.5.597"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Shankar U, Vijayasekar K, Bansal R, Walfish A. Treatment of rituximab-induced Crohn&apos;s disease with ustekinumab induction and long-term maintenance of remission. Inflamm Bowel Dis 26: e3, 2020.","DOI":"10.1093\/ibd\/izz270"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/5\/60_5119-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T04:08:35Z","timestamp":1615003715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/5\/60_5119-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5119-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}